|
Report Date : |
01.04.2014 |
IDENTIFICATION DETAILS
|
Name : |
PHARMACHEMICALS HANDELS GMBH |
|
|
|
|
Registered Office : |
Spaldingstr. 210, D 20097 Hamburg |
|
|
|
|
Country : |
Germany |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
1996 |
|
|
|
|
Com. Reg. No.: |
HRB 62976 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Wholesale of pharmaceutical goods |
|
|
|
|
No. of Employees : |
5 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2013
|
Country Name |
Previous Rating (30.06.2013) |
Current Rating (30.09.2013) |
|
Germany |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
GERMANY - ECONOMIC OVERVIEW
The German economy - the
fifth largest economy in the world in PPP terms and Europe's largest - is a leading
exporter of machinery, vehicles, chemicals, and household equipment and
benefits from a highly skilled labor force. Like its Western European
neighbors, Germany faces significant demographic challenges to sustained
long-term growth. Low fertility rates and declining net immigration are
increasing pressure on the country's social welfare system and necessitate
structural reforms. Reforms launched by the government of Chancellor Gerhard
SCHROEDER (1998-2005), deemed necessary to address chronically high
unemployment and low average growth, has contributed to strong growth and
falling unemployment. These advances, as well as a government subsidized,
reduced working hour scheme, help explain the relatively modest increase in
unemployment during the 2008-09 recession - the deepest since World War II -
and its decrease to 5.3% in 2013. The new German government introduced a
minimum wage of $11 per hour to take effect in 2015. Stimulus and stabilization
efforts initiated in 2008 and 2009 and tax cuts introduced in Chancellor Angela
MERKEL's second term increased Germany's total budget deficit - including
federal, state, and municipal - to 4.1% in 2010, but slower spending and higher
tax revenues reduced the deficit to 0.8% in 2011 and in 2012 Germany reached a
budget surplus of 0.1%. A constitutional amendment approved in 2009 limits the
federal government to structural deficits of no more than 0.35% of GDP per
annum as of 2016 though the target was already reached in 2012. Following the
March 2011 Fukushima nuclear disaster, Chancellor Angela MERKEL announced in
May 2011 that eight of the country's 17 nuclear reactors would be shut down
immediately and the remaining plants would close by 2022. Germany hopes to
replace nuclear power with renewable energy. Before the shutdown of the eight
reactors, Germany relied on nuclear power for 23% of its electricity generating
capacity and 46% of its base-load electricity production.
|
Source
: CIA |
PHARMACHEMICALS HANDELS GMBH
Company Status: active
Spaldingstr. 210
D 20097 Hamburg
Telephone:040/2369492
Telefax: 040/2369368
Homepage:
www.pharmachemicals-gmbh.de
E-mail:
info@pharmachemicals-gmbh.de
Business relations are permissible.
LEGAL FORM Private
limited company
Date of foundation: 1996
Shareholders'
agreement: 18.09.1996
Registered on: 06.12.1996
Commercial Register: Local court 20355 Hamburg
under: HRB 62976
Share capital: EUR 50,000.00
Shareholder:
Dr. Avraam Sarafidis
Grenzknick 7
D 22043 Hamburg
born: 18.11.1961
Share: EUR 50,000.00
Manager:
Dr. Avraam Sarafidis
Grenzknick 7
D 22043 Hamburg
having sole power of
representation
born: 18.11.1961
Profession: Chemist
Proxy:
Michaela Sarafidis
D 20097 Hamburg
having sole power of
representation
born: 26.06.1958
Proxy:
Eleni Sarafidis
D 20097 Hamburg
having sole power of
representation
born: 11.09.1985
11.07.1997 - 31.12.1998 TRANSPHARMA and CHEMICALS Handels
GmbH
Gotenstr. 13
D 20097 Hamburg
Private limited company
Main
industrial sector
46461
Wholesale of pharmaceutical goods
46760
Wholesale of other intermediate goods
Payment experience: within
agreed terms
Negative information: We have no negative information at hand.
Balance sheet year: 2011
Type of ownership: Tenant
Address Spaldingstr.
210
D 20097 Hamburg
Real Estate of: Dr.
Avraam Sarafidis
Type of ownership: unknown
Address
Grenzknick 7
D 22043 Hamburg
Land register documents were not available.
Principal bank
COMMERZBANK, 20454 HAMBURG
Sort. code: 20040000
BIC: COBADEHHXXX
Turnover: 2012
*EUR 1,220,000.00
Equipment: *EUR 28,000.00
Ac/ts receivable: EUR
3,846,778.00
Liabilities: EUR 933,483.00
Employees: 5
- Freelancer:
1
The business figures marked with an asterisk
are estimates based on average values in the line of business.
Balance sheet ratios 01.01.2011 - 31.12.2011
Equity ratio [%]: 73.55
Liquidity ratio: 10.00
Return on total capital [%]: 21.39
Balance sheet ratios 01.01.2010 - 31.12.2010
Equity ratio [%]: 61.84
Liquidity ratio: 10.00
Return on total capital [%]: 20.04
Balance sheet ratios 01.01.2009 - 31.12.2009
Equity ratio [%]: 59.71
Liquidity ratio: 8.94
Return
on total capital [%]: 20.20
Balance sheet ratios 01.01.2008 - 31.12.2008
Equity ratio [%]: 48.04
Liquidity ratio: 3.24
Return on total capital [%]: 16.03
Equity ratio
The equity ratio indicates the portion of the
equity as compared
to the total capital. The higher the equity
ratio, the better the
economic stability (solvency) and thus the
financial autonomy of
a company.
Liquidity ratio
The liquidity ratio shows the proportion
between adjusted
receivables and net liabilities. The higher
the ratio, the lower
the company's financial dependancy from
external creditors.
Return on total capital
The return on total capital shows the
efficiency and return on
the total capital employed in the company. The
higher the return
on total capital, the more economically does
the company work
with the invested capital.
Type of
balance sheet: Company
balance sheet
Financial
year: 01.01.2011 - 31.12.2011
ASSETS EUR 5,280,289.19
Fixed assets
EUR 76,788.12
Tangible assets
EUR 7,012.12
Other / unspecified tangible assets
EUR 7,012.12
Financial assets
EUR 69,776.00
Other / unspecified financial assets EUR 69,776.00
Current assets
EUR 5,181,291.46
Stocks
EUR 524,656.31
Accounts receivable
EUR 3,846,777.62
Other debtors and assets
EUR 3,846,777.62
Liquid means
EUR 809,857.53
Remaining other assets
EUR 22,209.61
Accruals (assets)
EUR 22,209.61
LIABILITIES EUR 5,280,289.19
Shareholders' equity
EUR 3,883,810.49
Capital
EUR 50,000.00
Subscribed capital (share capital)
EUR 50,000.00
Balance sheet profit/loss (+/-)
EUR 3,833,810.49
Profit / loss brought forward
EUR 2,704,482.23
Annual surplus / annual deficit
EUR 1,129,328.26
Provisions
EUR 462,995.51
Liabilities
EUR 933,483.19
Other liabilities
EUR 933,483.19
Unspecified other liabilities
EUR 933,483.19
Type of
balance sheet: Company
balance sheet
Financial
year: 01.01.2010 - 31.12.2010
ASSETS EUR 4,694,998.85
Fixed assets EUR 77,727.67
Tangible assets
EUR 7,951.67
Other / unspecified tangible assets
EUR 7,951.67
Financial assets
EUR 69,776.00
Other / unspecified financial assets EUR 69,776.00
Current assets
EUR 4,593,027.69
Stocks
EUR 501,252.18
Accounts receivable
EUR 3,251,522.51
Other debtors and assets EUR 3,251,522.51
Liquid means
EUR 840,253.00
Remaining other assets
EUR 24,243.49
Accruals (assets)
EUR 24,243.49
LIABILITIES EUR 4,694,998.85
Shareholders' equity
EUR 2,903,251.63
Capital
EUR 50,000.00
Subscribed capital (share capital)
EUR 50,000.00
Balance sheet profit/loss (+/-)
EUR 2,853,251.63
Profit / loss brought forward
EUR 1,912,574.14
Annual surplus / annual deficit
EUR 940,677.49
Provisions EUR 764,804.91
Liabilities
EUR 1,026,942.31
Other liabilities
EUR 1,026,942.31
Unspecified other liabilities
EUR 1,026,942.31
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.10 |
|
|
1 |
Rs.99.85 |
|
Euro |
1 |
Rs.82.58 |
INFORMATION DETAILS
|
Report Prepared
by : |
NNA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.